WELL Health Technologies Corp (WELL) AI Stock Analysis

• Market Cap: C$1.20B
• Dividend Yield: N/A
• Average Volume (3M): 994.48K
• Price to Earnings (P/E): 30.4
• Beta (1Y): 1.22
• Revenue Growth: 17.19%
• EPS Growth: -191.01%
• Country: CA
• Employees: 1,507
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 253,275,480
• 10 Day Avg. Volume: 628,947
• 30 Day Avg. Volume: 994,478
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.54
• Price Target Upside: 57.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 62 Neutral
• Price Target: C$5.00 ▲(4.38% Upside)

WELL Health Technologies Corp's stock is driven by strong corporate events and revenue growth potential. However, financial performance issues, technical analysis signals, and valuation concerns weigh down the overall score. The company's strategic initiatives and acquisitions could mitigate risks if executed successfully.

Positive Factors

Acquisitions

Two acquisitions were closed that are expected to add annual revenue of C$12M and adjusted EBITDA of C$3M.

Earnings

WELL Health Technologies reported 1Q25 results with revenue up 32% year-over-year and adjusted EBITDA of C$27.6M, beating estimates on the top line.

Innovation and Technology

The launch of Nexus AI, an AI-powered clinical documentation solution, and government funding support represents a focused effort on innovation and cost optimization.

Negative Factors

Divestiture

The potential sale of US businesses like Wisp and Circle Medical could improve the balance sheet with minimal impact on cash flow, providing significant capital to focus on Canadian growth.

Financial Guidance

Q1 revenue and EBITDA estimates are reduced by $6.5M.

Strategic Focus

The expansion of Canadian clinics is clearly the focus going forward, with plans to sell or spin off most other segments.

WELL Health Technologies Corp Business Overview & Revenue Model

Company Description

WELL Health Technologies Corp. operates as a practitioner focused digital health company in Canada, the United States, and internationally. It offers end-to-end omni-channel patient services, including primary care; physiotherapy, occupational therapy, chiropractic, dietary, mental health counselling, and sleep related services; specialized care, including gastroenterologists; diagnostic services related to cardiology, women's health, and bone/muscle health and cancer diagnostics; and telehealth services. The company also operates OSCAR Pro, an electronic medical records platform; telehealth platforms, including Tia Health, VirtualClinic+, VirtuelMed, Adracare, and Circle Medical; Apps.health, a digital health app marketplace; Insig, which offers virtual care and digital patient engagement services; billing and revenue cycle management solutions for billing and back-office services comprising billing-as-a-service outsourcing services to doctors; and cybersecurity protection and patient data privacy solutions. As of December 31, 2021, the company operated 30 primary care and executive care clinics; and provides primary care, specialty care, and accredited diagnostic health services through 49 locations across Ontario. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. WELL Health Technologies Corp. was incorporated in 2010 and is headquartered in Vancouver, Canada.

How the Company Makes Money

WELL Health Technologies Corp generates revenue through multiple streams. The primary revenue model includes fees from healthcare clinics, which offer various medical services to patients. Additionally, the company earns income through its digital health solutions, including subscription and licensing fees for its electronic medical records (EMR) software, which is used by healthcare providers to manage patient information. WELL also derives revenue from telehealth services, where patients are charged for virtual consultations. The company has established key partnerships with healthcare providers and technology firms to expand its service offerings and reach. The combination of these services and strategic partnerships allows WELL to maintain a diverse and stable revenue base.

WELL Health Technologies Corp Financial Statement Overview

Summary

WELL Health Technologies Corp exhibits strong revenue growth; however, profitability challenges persist, highlighted by negative EBIT and net income. The balance sheet is stable but increased debt levels could be a risk. Cash flow instability indicates the need for better operational efficiency.

Income Statement

WELL Health Technologies Corp has shown robust revenue growth, with a significant increase in total revenue from 2020 to TTM 2025. However, the company has struggled to maintain profitability, evidenced by negative EBIT and net income in the TTM period. Despite strong EBITDA in 2024, the negative trajectory in TTM indicates challenges in cost management or operational inefficiencies.

Balance Sheet

The balance sheet reflects a stable equity position with a consistent increase in stockholders' equity over the years. However, the debt levels have also increased, leading to a moderate debt-to-equity ratio, which could pose risks if profitability does not improve. The equity ratio remains healthy, indicating a solid asset base.

Cash Flow

Cash flow management shows mixed results. The company has positive operating cash flow but struggles with free cash flow, which turned negative in the TTM period. This indicates potential issues with capital expenditure or operating efficiency. The fluctuations in free cash flow growth suggest instability in cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	919.69M	776.05M	569.14M	302.32M	50.24M
Gross Profit	363.01M	372.27M	303.29M	153.69M	21.22M
EBITDA	122.52M	101.88M	95.99M	21.27M	-495.00K
Net Income	32.61M	82.00K	19.07M	-30.69M	-2.62M
Balance Sheet
Total Assets	1.81B	1.41B	1.32B	1.26B	262.73M
Cash, Cash Equivalents and Short-Term Investments	131.67M	43.42M	48.91M	61.92M	86.89M
Total Debt	425.09M	426.28M	358.42M	401.94M	23.57M
Total Liabilities	877.55M	563.16M	503.78M	554.37M	43.75M
Stockholders Equity	867.61M	767.67M	732.34M	618.24M	217.37M
Cash Flow
Free Cash Flow	-6.70M	37.20M	70.14M	19.59M	-6.52M
Operating Cash Flow	9.52M	66.44M	76.55M	22.27M	-5.38M
Investing Cash Flow	-60.23M	-106.42M	-37.93M	-499.78M	-44.21M
Financing Cash Flow	133.50M	10.63M	-52.85M	452.53M	120.84M

WELL Health Technologies Corp Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Positive. The current price of 4.79 is above the 20-day moving average (MA) of 4.71, above the 50-day MA of 4.33, and below the 200-day MA of 5.11, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 62.67 is Neutral, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DNTL	64 Neutral	C$1.63B	―	-3.31%	0.61%	9.88%	11.07%
WELL	62 Neutral	C$1.20B	30.45	-3.53%	―	17.19%	-191.01%
NLH	60 Neutral	C$19.65M	16.67	4.53%	―	4.09%	―
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.37%	15.48%	-2.68%
CRRX	51 Neutral	C$179.66M	―	-2.17%	―	-0.16%	75.25%
MFCSF	―	$205.64M	2.18	41.13%	2.37%	―	―
MEDI	―	$189.99M	―		―	―	―

WELL Health Technologies Corp Corporate Events

WELL Health to Release Q2 2025 Financial Results

WELL Health Technologies Corp. announced it will release its second quarter 2025 financial results on August 14, 2025. The company will hold a conference call and webcast to discuss the results, led by CEO Hamed Shahbazi and CFO Eva Fong. This announcement reflects WELL’s ongoing commitment to transparency and engagement with stakeholders, as it continues to expand its influence in the digital healthcare industry.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELLSTAR Updates 2025 Guidance Amid Strong Growth and Acquisitions

WELL Health Technologies Corp’s subsidiary, WELLSTAR, has updated its fiscal 2025 guidance, projecting $74 million in total revenue and $22 million in Adjusted EBITDA, driven by strong organic growth and a robust acquisition pipeline. The company has executed three letters of intent for acquisitions expected to significantly boost its annual recurring revenue and expand its digital health platform, while its Nexus AI solution is gaining traction among clinicians, positioning WELLSTAR as a leader in Canadian digital health.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies Reports Strong Growth and Expanded Credit Facility

WELL Health Technologies Corp has announced an update on its Canadian Clinics business, reflecting improved financial guidance and an expanded credit facility. The company is ahead of internal expectations, forecasting over $450 million in revenue and over $60 million in Adjusted EBITDA for fiscal 2025. This growth is driven by both organic expansion and strategic acquisitions, including two new clinics in British Columbia, contributing significantly to the company’s revenue and operational scale. Additionally, WELL has extended its credit facility to $200 million, supporting further expansion and cost optimization initiatives aimed at enhancing efficiency and operational excellence across its Canadian clinics.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies Corp Announces Successful Election of Directors

WELL Health Technologies Corp announced the successful election of its directors during the annual general meeting held on June 30, 2025. The voting results showed strong support for the nominees, with a significant portion of the company’s common shares voted by proxy. This outcome reinforces WELL Health’s governance and strategic direction, potentially strengthening its position in the digital healthcare industry.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Expands Primary Care Capacity with 45,000 New Patient Openings

WELL Health Technologies Corp. has announced a significant expansion in primary care capacity, adding over 45,000 new patient openings across its national clinic network in Ontario, Alberta, and Manitoba. This expansion is facilitated by investments in physician recruitment, including internationally trained doctors, and the implementation of advanced digital workflows and automation infrastructure. These efforts aim to address Canada’s access-to-care crisis by combining physician recruitment with digital health solutions to enhance care capacity and improve patient outcomes.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$7.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

CRH Medical and WovenX Partner to Enhance GI Care Access

CRH Medical Corporation, a subsidiary of WELL Health Technologies Corp, has partnered with WovenX Health to enhance gastrointestinal (GI) care access and streamline delivery. This strategic collaboration combines CRH’s GI solutions with WovenX’s virtual platform to improve patient access, operational efficiency, and care standards, offering a consumer-centric model that addresses long-standing barriers in the GI community.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies Appoints Ric Leong as Chief Accounting Officer

WELL Health Technologies Corp. has appointed Ric Leong as its Chief Accounting Officer to lead the company’s accounting operations and financial planning as it continues to grow through acquisitions. Leong, with a strong background in financial leadership from his previous roles at Hootsuite and Avigilon, will focus on strengthening WELL’s financial reporting and integration processes, enhancing financial planning and analysis capabilities, and supporting the company’s expansive acquisition strategy.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Subsidiaries Recognized in Canada Health Infoway’s 2025 Vendor Innovation Program

WELL Health Technologies Corp announced that its subsidiaries, Intrahealth, Pentavere, and OceanMD, have been selected for Canada Health Infoway’s 2025 Vendor Innovation Program. This recognition highlights the company’s leadership in the digital health sector, as their projects aim to enhance data quality, care coordination, and access to health information, thereby advancing interoperability in Canada’s healthcare system.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Initiates Automatic Share Purchase Plan to Boost Shareholder Value

WELL Health Technologies Corp. has entered into an automatic share purchase plan (ASPP) with a broker to facilitate the repurchase of its common shares under a previously announced normal course issuer bid (NCIB). This move allows the company to buy back up to 6,326,417 common shares, representing approximately 2.5% of its outstanding shares, during a 12-month period. The ASPP enables the broker to purchase shares even during periods when WELL is restricted from trading due to insider trading rules or internal blackout periods. This strategic initiative is expected to enhance shareholder value and reflects WELL’s confidence in its business prospects.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.